University of Auckland Scientist Dr Molly Swanson Secures $877K to Tackle Motor Neurone Disease

Auckland scientist Dr Molly Swanson leverages a personal rare disease diagnosis to lead innovative research into reversing toxic brain cell behavior in MND.

By: AXL Media

Published: Apr 7, 2026, 3:44 AM EDT

Source: Stuff

A Personal Intersection of Science and Medicine

For Dr Molly Swanson, a researcher at the University of Auckland’s Centre for Brain Research, the line between professional inquiry and personal experience blurred when her son James was diagnosed with LCHADD. This rare genetic disorder affects only two individuals in New Zealand, requiring constant management through feeding tubes and specialist care. Swanson notes that being on the "other side" of the medical world has fundamentally grounded her research philosophy, providing a deeper empathetic connection to the families she serves through her work on neurodegenerative conditions.

The Strategic Hunt for Toxic Microglia

The core of Swanson’s current research targets microglia, the brain's resident immune cells. While these cells typically function as the central nervous system's first line of defense—clearing debris and repairing damage—they can undergo a catastrophic shift in MND patients. Swanson’s data indicates that these cells often turn toxic, actively contributing to the death of motor neurons rather than protecting them. This cellular "betrayal" is a primary driver behind the rapid loss of movement, speech, and respiratory function associated with the disease.

TRANSFORMATIVE ANALYSIS: By focusing on the "switch" that turns microglia from helpers to killers, Swanson is moving away from traditional symptom management toward a disease-modifying strategy. If she can successfully identify the DNA sequence responsible for this toxicity, it opens the door for CRISPR-based gene editing or targeted pharmacology to "reset" the brain's immune environment. This approach is particularly critical for New Zealand, which remains a global outlier in MND mortality statistics.

Funding the Future of Neuro-Innovation